Douglas B Johnson

Douglas B Johnson

UNVERIFIED PROFILE

Are you Douglas B Johnson?   Register this Author

Register author
Douglas B Johnson

Douglas B Johnson

Publications by authors named "Douglas B Johnson"

Are you Douglas B Johnson?   Register this Author

100Publications

5143Reads

37Profile Views

Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma.

Oncologist 2019 Nov 18;24(11):1495-1496. Epub 2019 Jun 18.

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0332DOI Listing
November 2019

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.

J Immunother Cancer 2019 Nov 15;7(1):306. Epub 2019 Nov 15.

Vanderbilt University Medical Center, Department of Medicine, Division of Hematology and Oncology, 1301 Medical Center Drive, Nashville, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0805-8DOI Listing
November 2019

Cardiovascular Toxicities Associated With Ibrutinib.

J Am Coll Cardiol 2019 Oct;74(13):1667-1678

Departments of Medicine and Pharmacology, Cardio-Oncology program, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.07.056DOI Listing
October 2019

Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.

Cancer 2019 Oct 3. Epub 2019 Oct 3.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32542DOI Listing
October 2019

Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors.

Eur J Cancer 2019 Oct 31;123:112-115. Epub 2019 Oct 31.

Sorbonne Université, INSERM CIC-1421, AP-HP, Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital, Department of Pharmacology, UNICO-GRECO APHP.Sorbonne Cardio-oncology program, F-75013 Paris, France; Departments of Medicine and Oncology, Cardio-oncology Program, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.09.022DOI Listing
October 2019

Correlates of response and outcomes with talimogene laherperpvec.

J Surg Oncol 2019 Sep 2;120(3):558-564. Epub 2019 Jul 2.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.25601DOI Listing
September 2019

Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?

Am J Transplant 2019 Sep 24. Epub 2019 Sep 24.

Section of Surgical Sciences, Department of Surgery, Division of Hepatobiliary Surgery & Liver Transplantation, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15617DOI Listing
September 2019

Longer Survival With Anti-Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Association-In Reply.

JAMA Oncol 2019 Sep 26. Epub 2019 Sep 26.

Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.3817DOI Listing
September 2019

Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.

N Engl J Med 2019 06;380(24):2377-2379

Assistance Publique-Hôpitaux de Paris, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1901677DOI Listing
June 2019

Hematologic Complications of Immune Checkpoint Inhibitors.

Oncologist 2019 May 28;24(5):584-588. Epub 2019 Feb 28.

Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0574DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516131PMC
May 2019

Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.

Eur J Cancer 2019 May 4;113:10-13. Epub 2019 Apr 4.

Sorbonne Université, INSERM CIC Paris-Est, AP-HP, ICAN, Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital, Department of Pharmacology, F-75013 Paris, France; Departments of Medicine, Cardio-oncology Program, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.03.002DOI Listing
May 2019

Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates.

J Immunother Cancer 2019 May 7;7(1):123. Epub 2019 May 7.

Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0584-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503546PMC
May 2019

Immunotherapy in Older Adults with Cancer.

Curr Oncol Rep 2019 May 7;21(7):56. Epub 2019 May 7.

Division of Hematology/Oncology, Geriatrics, and Palliative Care, Institute of Cancer Outcomes and Survivorship, O'Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, 1600 7th Avenue South, Lowder 500, Birmingham, AL, 35233, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0806-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619507PMC
May 2019

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.

J Immunother Cancer 2019 May 22;7(1):134. Epub 2019 May 22.

Department of Medicine, Vanderbilt University Medical Center, 777 PRB, 2220 Pierce Ave, Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0617-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530194PMC
May 2019

Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Clin Cancer Res 2019 Apr 21;25(8):2392-2402. Epub 2018 Nov 21.

Department of Medicine, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467754PMC
April 2019

Cardiovascular toxicities associated with immune checkpoint inhibitors.

Cardiovasc Res 2019 Apr;115(5):854-868

Division of Cardiology, Cardio-Oncology Program, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cvr/cvz026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452314PMC
April 2019

Toxicities Associated With PD-1/PD-L1 Blockade.

Cancer J 2018 Jan/Feb;24(1):36-40

From the Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00130404-201801000-0000
Publisher Site
http://dx.doi.org/10.1097/PPO.0000000000000296DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784852PMC
March 2019

Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?

Clin Cancer Res 2019 Mar 26;25(5):1452-1454. Epub 2018 Dec 26.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-3858DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397678PMC
March 2019

Targeting tissue factor in advanced solid tumours.

Lancet Oncol 2019 Mar 8;20(3):318-319. Epub 2019 Feb 8.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30912-4DOI Listing
March 2019

Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.

Proc Natl Acad Sci U S A 2019 Mar 19;116(10):4583-4591. Epub 2019 Feb 19.

Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1821889116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410847PMC
March 2019

Adverse Events Associated With Immune Checkpoint Inhibitors-Reply.

JAMA 2019 03;321(12):1219-1220

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2018.22123DOI Listing
March 2019

Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.

J Natl Compr Canc Netw 2019 Feb;17(2):114-117

bDepartment of Medicine, University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7070DOI Listing
February 2019

Class Matters: Sensitivity of -Mutant Melanoma to MAPK Inhibition.

Clin Cancer Res 2018 12 24;24(24):6107-6109. Epub 2018 Jul 24.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1795DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295213PMC
December 2018

Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes.

Diabetes Care 2018 12 10;41(12):e150-e151. Epub 2018 Oct 10.

Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc18-1465DOI Listing
December 2018

Emerging biomarkers for cancer immunotherapy in melanoma.

Semin Cancer Biol 2018 10 14;52(Pt 2):207-215. Epub 2017 Sep 14.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States; Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, United States; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, TN, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2017.09.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851807PMC
October 2018

Immune Checkpoint Inhibitor Toxicity in 2018.

JAMA 2018 10;320(16):1702-1703

Department of Medicine, Northwestern University Medical Center, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.20
Publisher Site
http://dx.doi.org/10.1001/jama.2018.13995DOI Listing
October 2018

Melanoma: What do all the mutations mean?

Cancer 2018 09 17;124(17):3490-3499. Epub 2018 Apr 17.

Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31345
Publisher Site
http://dx.doi.org/10.1002/cncr.31345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191351PMC
September 2018

Continued Poor Survival in Metastatic Uveal Melanoma: Implications for Molecular Prognostication, Surveillance Imaging, Adjuvant Therapy, and Clinical Trials.

JAMA Ophthalmol 2018 09;136(9):986-988

Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaophthalmol.2018.1813DOI Listing
September 2018

Toxicities and outcomes: Do steroids matter?

Cancer 2018 09 5;124(18):3638-3640. Epub 2018 Jul 5.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214744PMC
September 2018

Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply.

Lancet 2018 08;392(10145):384-385

Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)31556-3DOI Listing
August 2018

Biomarkers for immune therapy in melanoma.

Semin Cutan Med Surg 2018 Jun;37(2):120-126

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee, USA.

View Article

Download full-text PDF

Source
https://scmsjournal.com/article/abstract/biomarkers-for-immu
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.019DOI Listing
June 2018

Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.

J Immunother Cancer 2017 17;5. Epub 2017 Jan 17.

Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232 USA ; Vanderbilt-Ingram Cancer Center, 777 Preston Research Building, 2220 Pierce Avenue, Nashville, TN 37232 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0206-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240268PMC
April 2018

Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.

Am J Clin Dermatol 2018 Apr;19(2):181-193

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-017-0320-y
Publisher Site
http://dx.doi.org/10.1007/s40257-017-0320-yDOI Listing
April 2018

Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease.

Oncology (Williston Park) 2018 04;32(4):190-4

View Article

Download full-text PDF

Source
April 2018

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

J Clin Oncol 2018 03 9;36(7):667-673. Epub 2017 Oct 9.

Georgina V. Long, University of Sydney, and Royal North Shore Hospital; Richard Kefford, Macquarie University, Sydney, and Westmead Hospital, Westmead, New South Wales; Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia; Zeynep Eroglu, Moffitt Cancer Center, Tampa, FL; Jeffrey Infante, Tennessee Oncology; Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, TN; Sapna Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Adil Daud, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, University of Colorado, Denver, CO; Lynn Schuchter, University of Pennsylvania, Philadelphia, PA; William Sharfman, Sidney Kimmel Cancer Center, Baltimore, MD; Robert McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University, New Haven, CT; Suman Redhu, Eduard Gasal, and Bijoyesh Mookerjee, Novartis, East Hanover, NJ; Jeffrey Weber, New York University Langone Medical Center, New York, NY; and Keith T. Flaherty, Dana-Farber/Harvard Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.1025
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.1025DOI Listing
March 2018

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.

Lancet 2018 03;391(10124):933

Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)30533-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668330PMC
March 2018

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.

J Immunother Cancer 2016 18;4:60. Epub 2016 Oct 18.

Departments of Medicine, Vanderbilt Ingram Cancer Center, 777 PRB, 2220 Pierce Ave., Nashville, TN 37232 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0166-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067899PMC
February 2018

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:
Shona Hendry Roberto Salgado Thomas Gevaert Prudence A Russell Tom John Bibhusal Thapa Michael Christie Koen van de Vijver M V Estrada Paula I Gonzalez-Ericsson Melinda Sanders Benjamin Solomon Cinzia Solinas Gert G G M Van den Eynden Yves Allory Matthias Preusser Johannes Hainfellner Giancarlo Pruneri Andrea Vingiani Sandra Demaria Fraser Symmans Paolo Nuciforo Laura Comerma E A Thompson Sunil Lakhani Seong-Rim Kim Stuart Schnitt Cecile Colpaert Christos Sotiriou Stefan J Scherer Michail Ignatiadis Sunil Badve Robert H Pierce Giuseppe Viale Nicolas Sirtaine Frederique Penault-Llorca Tomohagu Sugie Susan Fineberg Soonmyung Paik Ashok Srinivasan Andrea Richardson Yihong Wang Ewa Chmielik Jane Brock Douglas B Johnson Justin Balko Stephan Wienert Veerle Bossuyt Stefan Michiels Nils Ternes Nicole Burchardi Stephen J Luen Peter Savas Frederick Klauschen Peter H Watson Brad H Nelson Carmen Criscitiello Sandra O'Toole Denis Larsimont Roland de Wind Giuseppe Curigliano Fabrice André Magali Lacroix-Triki Mark van de Vijver Federico Rojo Giuseppe Floris Shahinaz Bedri Joseph Sparano David Rimm Torsten Nielsen Zuzana Kos Stephen Hewitt Baljit Singh Gelareh Farshid Sibylle Loibl Kimberly H Allison Nadine Tung Sylvia Adams Karen Willard-Gallo Hugo M Horlings Leena Gandhi Andre Moreira Fred Hirsch Maria V Dieci Maria Urbanowicz Iva Brcic Konstanty Korski Fabien Gaire Hartmut Koeppen Amy Lo Jennifer Giltnane Marlon C Rebelatto Keith E Steele Jiping Zha Kenneth Emancipator Jonathan W Juco Carsten Denkert Jorge Reis-Filho Sherene Loi Stephen B Fox

Adv Anat Pathol 2017 Nov;24(6):311-335

Departments of *Pathology §§§Medical Oncology, Peter MacCallum Cancer Centre, Melbourne †The Sir Peter MacCallum Department of Oncology Departments of **Pathology ∥∥Medicine, University of Melbourne ¶¶Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville #Department of Anatomical Pathology, St Vincent's Hospital Melbourne, Fitzroy ††Department of Medical Oncology, Austin Health ‡‡Olivia Newton-John Cancer Research Institute, Heidelberg §§School of Cancer Medicine, La Trobe University, Bundoora §§§§§Centre for Clinical Research and School of Medicine, The University of Queensland ∥∥∥∥∥Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane §§§§§§§§§§The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst ∥∥∥∥∥∥∥∥∥∥Australian Clinical Labs, Bella Vista ‡‡‡‡‡‡‡‡‡‡‡‡Directorate of Surgical Pathology, SA Pathology §§§§§§§§§§§§Discipline of Medicine, Adelaide University, Adelaide, Australia ***********Department of Surgical Oncology, Netherlands Cancer Institute †††††††††††††Department of Pathology ##Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands ###Université Paris-Est ****INSERM, UMR 955 ††††Département de pathologie, APHP, Hôpital Henri-Mondor, Créteil ∥∥∥∥∥∥∥∥∥Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay ¶¶¶¶¶¶¶¶¶¶INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif ##########Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre †††††††Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre ‡‡‡‡‡‡‡University of Auvergne UMR1240, Clermont-Ferrand, France ‡‡‡‡Department of Medicine, Clinical Division of Oncology §§§§Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna ††††††††††††††Institute of Pathology, Medical University of Graz, Austria ∥∥∥∥European Institute of Oncology ¶¶¶¶School of Medicine ######Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan ¶¶¶¶¶¶¶¶¶¶¶¶¶Department of Surgery, Oncology and Gastroenterology, University of Padova #############Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy †††††Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona †††††††††††Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain §Department of Pathology and TCRU, GZA ¶¶¶Department of Pathology, GZA Ziekenhuizen, Antwerp ∥Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven ‡‡‡‡‡‡‡‡‡‡‡Department of Pathology, University Hospital Leuven, Leuven, Belgium ¶Department of Pathology, AZ Klina, Brasschaat ††††††Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk ∥∥∥Molecular Immunology Unit ‡‡‡‡‡‡Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles ‡Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet **************European Organisation for Research and Treatment of Cancer (EORTC) Headquarters *******Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium §§§§§§§Department of Surgery, Kansai Medical School, Hirakata, Japan #######Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea ∥∥∥∥∥∥∥∥Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center ¶¶¶¶¶¶¶¶Institute of Oncology, Gliwice Branch, Gliwice, Poland ‡‡‡‡‡‡‡‡‡‡‡‡‡‡Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg †††††††††Institute of Pathology, Charité Universitätsmedizin Berlin ‡‡‡‡‡‡‡‡‡VMscope GmbH, Berlin ¶¶¶¶¶¶¶¶¶German Breast Group GmbH, Neu-Isenburg, Germany **********Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency ††††††††††Department of Biochemistry and Microbiology, University of Victoria, Victoria Departments of ‡‡‡‡‡‡‡‡‡‡Medical Genetics #########Pathology and Laboratory Medicine ¶¶¶¶¶¶¶¶¶¶¶Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC ###########Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada §§§§§§§§§§§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar ‡‡‡‡‡‡‡‡Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center §§§§§§§§Warren Alpert Medical School of Brown University, Providence ¶¶¶¶¶National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA †††Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Departments of ‡‡‡Pathology, Microbiology and Immunology ########Department of Medicine, Vanderbilt University Medical Centre *********Vanderbilt Ingram Cancer Center, Nashville §§§§§§§§§Department of Pathology, Yale University School of Medicine, New Haven ∥∥∥∥∥∥∥∥∥∥∥Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine ∥∥∥∥∥∥∥Montefiore Medical Center ¶¶¶¶¶¶¶The Albert Einstein College of Medicine, Bronx, NY ********Department of Pathology, Brigham and Women's Hospital #####Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center ******Harvard Medical School ¶¶¶¶¶¶¶¶¶¶¶¶Division of Hematology-Oncology, Beth Israel Deaconess Medical Center ††††††††Department of Cancer Biology ‡‡‡‡‡‡‡‡‡‡‡‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO ‡‡‡‡‡Department of Cancer Biology, Mayo Clinic, Jacksonville, FL ∥∥∥∥∥∥Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN ¶¶¶¶¶¶Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA ††††††††††††Department of Pathology, New York University Langone Medical Centre ############New York University Medical School *************Perlmutter Cancer Center §§§§§§§§§§§§§Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University ***************Department of Pathology, Memorial Sloan-Kettering Cancer Center ####Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY *****Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX ∥∥∥∥∥∥∥∥∥∥∥∥Pathology Department, Stanford University Medical Centre, Stanford ∥∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Pathology, Stanford University, Palo Alto ***Department of Pathology, School of Medicine, University of California, San Diego §§§§§§§§§§§§§§Research Pathology, Genentech Inc., South San Francisco, CA *************Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda ¶¶¶¶¶¶¶¶¶¶¶¶¶¶Translational Sciences, MedImmune, Gaithersberg, MD §§§§§§Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover ##############Translational Medicine, Merck & Co. Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638696PMC
November 2017

MDM2 Antagonists Counteract Drug-Induced DNA Damage.

EBioMedicine 2017 Oct 19;24:43-55. Epub 2017 Sep 19.

Tennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, TN, United States; Vanderbilt University School of Medicine, Department of Cancer Biology, Nashville, TN, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2017.09.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652019PMC
October 2017

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Authors:
Shona Hendry Roberto Salgado Thomas Gevaert Prudence A Russell Tom John Bibhusal Thapa Michael Christie Koen van de Vijver M V Estrada Paula I Gonzalez-Ericsson Melinda Sanders Benjamin Solomon Cinzia Solinas Gert G G M Van den Eynden Yves Allory Matthias Preusser Johannes Hainfellner Giancarlo Pruneri Andrea Vingiani Sandra Demaria Fraser Symmans Paolo Nuciforo Laura Comerma E A Thompson Sunil Lakhani Seong-Rim Kim Stuart Schnitt Cecile Colpaert Christos Sotiriou Stefan J Scherer Michail Ignatiadis Sunil Badve Robert H Pierce Giuseppe Viale Nicolas Sirtaine Frederique Penault-Llorca Tomohagu Sugie Susan Fineberg Soonmyung Paik Ashok Srinivasan Andrea Richardson Yihong Wang Ewa Chmielik Jane Brock Douglas B Johnson Justin Balko Stephan Wienert Veerle Bossuyt Stefan Michiels Nils Ternes Nicole Burchardi Stephen J Luen Peter Savas Frederick Klauschen Peter H Watson Brad H Nelson Carmen Criscitiello Sandra O'Toole Denis Larsimont Roland de Wind Giuseppe Curigliano Fabrice André Magali Lacroix-Triki Mark van de Vijver Federico Rojo Giuseppe Floris Shahinaz Bedri Joseph Sparano David Rimm Torsten Nielsen Zuzana Kos Stephen Hewitt Baljit Singh Gelareh Farshid Sibylle Loibl Kimberly H Allison Nadine Tung Sylvia Adams Karen Willard-Gallo Hugo M Horlings Leena Gandhi Andre Moreira Fred Hirsch Maria V Dieci Maria Urbanowicz Iva Brcic Konstanty Korski Fabien Gaire Hartmut Koeppen Amy Lo Jennifer Giltnane Marlon C Rebelatto Keith E Steele Jiping Zha Kenneth Emancipator Jonathan W Juco Carsten Denkert Jorge Reis-Filho Sherene Loi Stephen B Fox

Adv Anat Pathol 2017 Sep;24(5):235-251

Departments of *Pathology §§§Medical Oncology, Peter MacCallum Cancer Centre, Melbourne †The Sir Peter MacCallum Department of Oncology Departments of **Pathology ∥∥Medicine, University of Melbourne ¶¶Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville #Department of Anatomical Pathology, St Vincent's Hospital Melbourne, Fitzroy ††Department of Medical Oncology, Austin Health ‡‡Olivia Newton-John Cancer Research Institute, Heidelberg §§School of Cancer Medicine, La Trobe University, Bundoora §§§§§Centre for Clinical Research and School of Medicine, The University of Queensland ∥∥∥∥∥Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane §§§§§§§§§§The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst ∥∥∥∥∥∥∥∥∥∥Australian Clinical Labs, Bella Vista ‡‡‡‡‡‡‡‡‡‡‡‡Directorate of Surgical Pathology, SA Pathology §§§§§§§§§§§§Discipline of Medicine, Adelaide University, Adelaide, Australia ***********Department of Surgical Oncology, Netherlands Cancer Institute †††††††††††††Department of Pathology ##Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands ###Université Paris-Est ****INSERM, UMR 955 ††††Département de pathologie, APHP, Hôpital Henri-Mondor, Créteil ∥∥∥∥∥∥∥∥∥Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay ¶¶¶¶¶¶¶¶¶¶INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif ##########Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre †††††††Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre ‡‡‡‡‡‡‡University of Auvergne UMR1240, Clermont-Ferrand, France ‡‡‡‡Department of Medicine, Clinical Division of Oncology §§§§Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna ††††††††††††††Institute of Pathology, Medical University of Graz, Austria ∥∥∥∥European Institute of Oncology ¶¶¶¶School of Medicine ######Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan ¶¶¶¶¶¶¶¶¶¶¶¶¶Department of Surgery, Oncology and Gastroenterology, University of Padova #############Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy †††††Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona †††††††††††Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain §Department of Pathology and TCRU, GZA ¶¶¶Department of Pathology, GZA Ziekenhuizen, Antwerp ∥Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven ‡‡‡‡‡‡‡‡‡‡‡Department of Pathology, University Hospital Leuven, Leuven, Belgium ¶Department of Pathology, AZ Klina, Brasschaat ††††††Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk ∥∥∥Molecular Immunology Unit ‡‡‡‡‡‡Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles ‡Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet **************European Organisation for Research and Treatment of Cancer (EORTC) Headquarters *******Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium §§§§§§§Department of Surgery, Kansai Medical School, Hirakata, Japan #######Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea ∥∥∥∥∥∥∥∥Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center ¶¶¶¶¶¶¶¶Institute of Oncology, Gliwice Branch, Gliwice, Poland ‡‡‡‡‡‡‡‡‡‡‡‡‡‡Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg †††††††††Institute of Pathology, Charité Universitätsmedizin Berlin ‡‡‡‡‡‡‡‡‡VMscope GmbH, Berlin ¶¶¶¶¶¶¶¶¶German Breast Group GmbH, Neu-Isenburg, Germany **********Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency ††††††††††Department of Biochemistry and Microbiology, University of Victoria, Victoria Departments of ‡‡‡‡‡‡‡‡‡‡Medical Genetics #########Pathology and Laboratory Medicine ¶¶¶¶¶¶¶¶¶¶¶Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC ###########Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada §§§§§§§§§§§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar ‡‡‡‡‡‡‡‡Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center §§§§§§§§Warren Alpert Medical School of Brown University, Providence ¶¶¶¶¶National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA †††Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Departments of ‡‡‡Pathology, Microbiology and Immunology ########Department of Medicine, Vanderbilt University Medical Centre *********Vanderbilt Ingram Cancer Center, Nashville §§§§§§§§§Department of Pathology, Yale University School of Medicine, New Haven ∥∥∥∥∥∥∥∥∥∥∥Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine ∥∥∥∥∥∥∥Montefiore Medical Center ¶¶¶¶¶¶¶The Albert Einstein College of Medicine, Bronx, NY ********Department of Pathology, Brigham and Women's Hospital #####Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center ******Harvard Medical School ¶¶¶¶¶¶¶¶¶¶¶¶Division of Hematology-Oncology, Beth Israel Deaconess Medical Center ††††††††Department of Cancer Biology ‡‡‡‡‡‡‡‡‡‡‡‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO ‡‡‡‡‡Department of Cancer Biology, Mayo Clinic, Jacksonville, FL ∥∥∥∥∥∥Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN ¶¶¶¶¶¶Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA ††††††††††††Department of Pathology, New York University Langone Medical Centre ############New York University Medical School *************Perlmutter Cancer Center §§§§§§§§§§§§§Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University ***************Department of Pathology, Memorial Sloan-Kettering Cancer Center ####Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY *****Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX ∥∥∥∥∥∥∥∥∥∥∥∥Pathology Department, Stanford University Medical Centre, Stanford ∥∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Pathology, Stanford University, Palo Alto ***Department of Pathology, School of Medicine, University of California, San Diego §§§§§§§§§§§§§§Research Pathology, Genentech Inc., South San Francisco, CA *************Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda ¶¶¶¶¶¶¶¶¶¶¶¶¶¶Translational Sciences, MedImmune, Gaithersberg, MD §§§§§§Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover ##############Translational Medicine, Merck & Co. Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564448PMC
September 2017

Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.

Oncoimmunology 2017 5;6(10):e1344805. Epub 2017 Jul 5.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2017.1344805DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665065PMC
July 2017

Immune checkpoint inhibitors in challenging populations.

Cancer 2017 06 27;123(11):1904-1911. Epub 2017 Feb 27.

Department of Medicine, Melanoma Institute Australia, University of Sydney Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30642DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445005PMC
June 2017

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

N Engl J Med 2017 06;376(23):2211-2222

From the John Wayne Cancer Institute at Saint John's Health Center, Santa Monica (M.B.F., D.S.B.H.), and the Departments of Pathology (A.J.C.), Biomathematics (H.-J.W., D.A.E., R.M.E.), and Medicine (D.A.E.), University of California, Los Angeles - both in California; Melanoma Institute Australia and the University of Sydney, Sydney (J.F.T., O.E.N.), Peter MacCallum Cancer Centre, Melbourne, VIC (M.H.), Princess Alexandra Hospital, Brisbane, QLD (B.M.S.), and Newcastle Melanoma Unit, Waratah, NSW (P.H.) - all in Australia; Huntsman Cancer Institute, Salt Lake City (R.H.A., R.D.N.), and Intermountain Healthcare Cancer Services-Intermountain Medical Center, Murray (T.L.B.) - both in Utah; Istituto Nazionale dei Tumori Napoli, Naples (N.M.), Istituto Europeo di Oncologia, Milan (A.T.), and Istituto Oncologico Veneto-University of Padua, Padua (C.R.R.) - all in Italy; H. Lee Moffitt Cancer Center, Tampa, FL (J.S.Z.); Helsinki University Hospital, Helsinki (T.J.); Dallas Surgical Group, Dallas (P.D.B.); Universitair Medisch Centrum Groningen, Groningen (H.J.H.), and Netherlands Cancer Institute, Amsterdam (M.W.J.M.W.) - both in the Netherlands; Norfolk and Norwich University Hospital, Norwich (M. Moncrieff), and Guy's and St. Thomas' NHS Foundation Trust, London (A.M.-R.) - both in the United Kingdom; Swedish Melanoma Study Group-University Hospital Lund, Lund, Sweden (C.I.); University of Michigan, Ann Arbor (M.S.S.); Wake Forest University, Winston-Salem (E.A.L.), and Duke University, Durham (R.S.) - both in North Carolina; Ohio State University, Columbus (D.A.); University of Zurich, Zurich (R.D.), and Centre Hospitalier Universitaire Vaudois, Lausanne (M. Matter) - both in Switzerland; Penn State Hershey Cancer Institute, Hershey (R.I.N.), Thomas Jefferson University (A.C.B.) and Fox Chase Cancer Center (J.M.F.), Philadelphia, and St. Luke's University Health Network, Bethlehem (D.C.D.) - all in Pennsylvania; Greenville Health System Cancer Center, Greenville, SC (S.D.T.); Sunnybrook Research Institute, Toronto (F.W.), and Tom Baker Cancer Centre, Calgary, AB (G.M.) - both in Canada; University of Washington, Seattle (D.R.B.); Saint Louis University, St. Louis (E.H.); Vanderbilt University (D.B.J., M.C.K.), Nashville, and University of Tennessee, Knoxville (J.M.L.) - both in Tennessee; University Hospital Schleswig-Holstein-Campus Lübeck, Lübeck (P.T.), University Hospital of Würzburg, Würzburg (A.G.), and City Hospital of Nürnberg, Nuremberg (E.S.) - all in Germany; SUNY at Stony Brook Hospital Medical Center, Stony Brook (T.L.H.), Memorial Sloan Kettering Cancer Center, New York (C.E.A.), and Roswell Park Cancer Institute, Buffalo (J.M.K.) - all in New York; Northwestern University Feinberg School of Medicine (J.D.W.) and Rush University Medical Center (S.D.B.), Chicago; University of Wisconsin, Madison (H.B.N.); Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (S.S.); M.D. Anderson Medical Center, Houston (J.E.G.); Johns Hopkins University School of Medicine, Baltimore (L.J.); University of Louisville, Louisville, KY (K.M.M.); Dartmouth-Hitchcock Medical Center, Lebanon, NH (R.J.B.); Hospital Clinic Barcelona, Barcelona (S.V.-S.); and Sentara CarePlex Hospital, Hampton, VA (R.A.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613210DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548388PMC
June 2017

When to consider alternatives to front-line immune therapies in metastatic melanoma.

Melanoma Manag 2017 May 10;4(2):71-74. Epub 2017 May 10.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2017-0005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094648PMC
May 2017

Enabling a genetically informed approach to cancer medicine: evaluation of the impact of comprehensive tumor sequencing.

Per Med 2017 May 5;14(3):189-192. Epub 2017 May 5.

Department of Medicine, Vanderbilt University Medical Center & Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pme-2017-0014
Publisher Site
http://dx.doi.org/10.2217/pme-2017-0014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573119PMC
May 2017

Cardiovascular Toxicities Associated with Cancer Immunotherapies.

Curr Cardiol Rep 2017 03;19(3):21

Divisions of Oncology, Department of Medicine, Vanderbilt University Medical Center, 2220 Pierce Ave, 777 Preston Research Bldg., Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11886-017-0835-0DOI Listing
March 2017

PD-1/PD-L1 blockade in renal cell cancer.

Expert Rev Clin Immunol 2017 Jan 28;13(1):77-84. Epub 2016 Jul 28.

b Department of Medicine , Northwestern University Medical Center , Chicago , IL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2016.1214575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555220PMC
January 2017

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.

J Immunother 2017 01;40(1):31-35

*Vanderbilt University Medical Center, Nashville, TN †Beth Israel Deaconess Medical Center ‡Dana-Farber Cancer Institute §Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/immunotherapy-journal/2017/0100
Web Search
http://dx.doi.org/10.1097/CJI.0000000000000148DOI Listing
January 2017

Myocarditis with Immune Checkpoint Blockade.

N Engl J Med 2017 01;376(3):292

Vanderbilt School of Medicine, Nashville, TN

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1615251DOI Listing
January 2017

Advances in the development of intralesional therapies for melanoma.

Melanoma Manag 2016 Dec 29;3(4):259-266. Epub 2016 Nov 29.

Department of Medicine, Vanderbilt University Medical Center, 777 PRB, 2220 Pierce Ave, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2016-0020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094591PMC
December 2016

Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

N Engl J Med 2016 Nov;375(18):1749-1755

From the Departments of Medicine (D.B.J., J.M.B., M.H., I.P., M.R.A., T.L.B., J.R.B., D.A.S., E.J.P., M.A.P., D.M.R., J.A.S., J.J.M.), Cancer Biology (J.M.B., J.J.M.), Pathology, Microbiology, and Immunology (M.L.C., L.C.-O., R.D.H.), Biostatistics (Y.X.), Pharmacology (D.M.R.), and Biomedical Informatics (Y.X., D.M.R.), the Cardio-oncology Program (D.A.S., J.J.M.), the Breast Cancer Research Program (J.M.B.), and the Center for Quantitative Sciences (Y.X.), Vanderbilt University Medical Center, Nashville; the Department of Medicine (S.C.) and the Division of Neuroimmunology (S.C., I.J.K.), Beth Israel Deaconess Medical Center, the Departments of Medicine (B.A.O., C.E.S., J.G.S.) and Pathology (A.H.L.), Brigham and Women's Hospital, the Department of Genetics, Harvard Medical School (J.G., C.E.S., J.G.S.) - all in Boston; Howard Hughes Medical Institute, Chevy Chase, MD (C.E.S.); Bristol-Myers Squibb, New York (N.K., G.P., D.S.R., J.S.D.); Neon Therapeutics, Cambridge, MA (R.P.D.); and the Departments of Pathology (J.M.T., R.A.A.), Dermatology (J.M.T.), and Oncology (L.A.D.), Johns Hopkins University, Baltimore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5247797PMC
November 2016

Responses to immune checkpoint inhibitors in nonagenarians.

Oncoimmunology 2016 18;5(11):e1234572. Epub 2016 Oct 18.

Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2016.1234572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139628PMC
October 2016

Melanoma driver mutations and immune therapy.

Oncoimmunology 2016 May 10;5(5):e1051299. Epub 2016 Mar 10.

Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center , Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1051299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910708PMC
May 2016